Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Nakamura N, Kanemura N, Matsumoto T, Nakamura H, Ikoma Y, Shibata Y, Kitagawa J, Kasahara S, Yamada T, Sawada M, Kaneda Y, Fukuno K, Takada E, Goto H, Lee S, Fujita K, Morishita T, Hara T, Tsurumi H, Shimizu M. Nakamura N, et al. Among authors: goto h. Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5. Sci Rep. 2023. PMID: 37925551 Free PMC article.
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Nannya Y, Katsumura N, Takahashi T, Kito Y, Takami T, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H. Hara T, et al. Among authors: goto h. Hematol Oncol. 2018 Oct;36(4):638-644. doi: 10.1002/hon.2524. Epub 2018 Jun 8. Hematol Oncol. 2018. PMID: 29882279 Clinical Trial.
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H. Sawada M, et al. Among authors: goto h. Eur J Haematol. 2002 Jun;68(6):354-61. doi: 10.1034/j.1600-0609.2002.01654.x. Eur J Haematol. 2002. PMID: 12225393 Free article. Clinical Trial.
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H. Goto H, et al. Among authors: goto n. J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9. doi: 10.1007/s00432-004-0600-9. Epub 2004 Oct 21. J Cancer Res Clin Oncol. 2005. PMID: 15503137
Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Goto H, Fukuno K, Kitagawa J, Yasuda I, Katsumura N, Takemura M, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: goto n, goto h. J Cancer Res Clin Oncol. 2009 Oct;135(10):1421-8. doi: 10.1007/s00432-009-0586-4. Epub 2009 Apr 21. J Cancer Res Clin Oncol. 2009. PMID: 19381687
Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Goto H, Fukuno K, Yamada T, Sawada M, Takahashi T, Takami T, Moriwaki H. Kasahara S, et al. Among authors: goto n, goto h. Leuk Lymphoma. 2011 Apr;52(4):629-34. doi: 10.3109/10428194.2011.555024. Leuk Lymphoma. 2011. PMID: 21438831 Clinical Trial.
Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T, Fukuno K, Takahashi T, Kito Y, Takami T, Moriwaki H. Goto N, et al. Among authors: goto h. Ann Hematol. 2012 May;91(5):705-714. doi: 10.1007/s00277-011-1363-4. Epub 2011 Dec 21. Ann Hematol. 2012. PMID: 22183251
A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
Tsurumi H, Hara T, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Shimizu M, Takahashi T, Takami T, Moriwaki H. Tsurumi H, et al. Among authors: goto n, goto h. Leuk Lymphoma. 2012 Feb;53(2):247-53. doi: 10.3109/10428194.2011.606383. Leuk Lymphoma. 2012. PMID: 21827339 Clinical Trial.
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Yasuda I, Katsumura N, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: goto n, goto h. J Cancer Res Clin Oncol. 2010 Jan;136(1):65-70. doi: 10.1007/s00432-009-0637-x. J Cancer Res Clin Oncol. 2010. PMID: 19590893 Clinical Trial.
3,623 results